Dr Lalchandani Labs Limited opened a new strategic centre at Vardhman Star City Mall in Dwarka, New Delhi, on May 28, 2026, to expand its geographic presence. The facility targets the large Government employee population residing in Dwarka and surrounding areas, regions where the company has historically received limited business. This expansion is expected to generate business of approximately Rs 1 Crore per annum, contributing to overall growth and market penetration.

The new centre aims to enhance customer outreach, improve accessibility, and deliver efficient services to clients in the region. The company believes the strategic location will significantly strengthen brand visibility and business development initiatives in West Delhi. Arjan Lalchandani, Managing Director, stated that the opening is an important step towards expanding the company's footprint in high-potential markets.

Business Expectations

The company has outlined specific financial targets for the new facility:

About Dr Lalchandani Labs Limited

Dr Lalchandani Labs Ltd is a Delhi-based integrated diagnostic healthcare company engaged in providing pathology and diagnostic testing services. The company operates through NABL Accredited diagnostic laboratories, collection centres, and institutional partnerships. It offers a comprehensive portfolio of diagnostic services including biochemistry, hematology, immunology, microbiology, molecular diagnostics, hormone assays, and preventive health packages, supported by modern diagnostic infrastructure.

Dr Lalchandani Labs Limited has submitted a formal clarification to BSE Limited, confirming that the company does not qualify as a "Large Corporate" under the criteria prescribed by SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, and its subsequent amendments. The disclosure was made on May 04, 2026, and pertains to the regulatory framework governing fund raising through the issuance of debt securities by large entities.

Basis of Non-Applicability

The company's classification is determined by the level of its long-term borrowings as on March 31, 2026. As per the SEBI circular, entities with long-term borrowings of Rs. 1000 crores or above are categorised as Large Corporates and are subject to mandatory debt market fundraising requirements. Dr Lalchandani Labs has confirmed that its long-term borrowings fall below this prescribed threshold, thereby exempting it from the obligations applicable to Large Corporates.

The key details of the disclosure are summarised below:

Regulatory Context

SEBI introduced the Large Corporate framework to encourage listed entities with significant borrowings to raise a portion of their incremental borrowings through the debt securities market. The circular mandates that companies meeting the threshold criteria comply with specific fundraising norms via the issuance of debt instruments. Companies that do not meet the borrowing threshold are required to submit a declaration confirming their non-applicability, which Dr Lalchandani Labs has duly filed with the exchange.

The disclosure was digitally signed by Managing Director Arjan Lalchandani on May 04, 2026, and submitted to BSE Limited for record and reference purposes.